Board of Directors

• Charles Ardai – Chairman of the Board

  Charles Ardai is the chairman of Schrödinger, Inc. He also serves as a managing director in the D. E. Shaw group, a specialized investment and technology development firm whose activities center on various aspects of the intersection between technology and finance. Prior to joining Schrödinger, he served as president and chief executive officer of Juno Online Services, Inc., a publicly traded technology firm he founded in 1995. He graduated summa cum laude from Columbia University in 1991.

• Ramy Farid – President and Board Member

  Ramy Farid, President, joined Schrödinger in 2002. He received his Ph.D. in Chemistry from Caltech in 1991, and was an NIH Postdoctoral Fellow at the University of Pennsylvania. He was an Assistant Professor at Rutgers University prior to joining Schrödinger. His research at Rutgers focused on computational protein design, which resulted in a number of high-profile publications. After joining Schrödinger, Ramy rapidly rose through a series of leadership positions as well as led many research and development projects; he also authored several highly-cited publications applying computational tools to drug discovery.

• Richard A. Friesner – Board Member

  Richard A. Friesner is Professor of Chemistry at Columbia University and Director of the Columbia Center for Biomolecular Simulation. He is a member of the American Academy of Arts of Sciences and has been awarded a Sloan Foundation Fellowship, Camille and Henry Dreyfus Teacher-Scholar Award, and an NIH Research Career Development Award. Current interests include quantum chemistry, development of potential functions for molecular simulation, continuum electrostatic models, and protein folding. Dr. Friesner is a co-founder of Schrödinger, and Chairman of Schrödinger's Scientific Advisory Board.

• Boris Nikolic – Board Member

  Dr. Boris Nikolic is a Scientific Advisor to Bill Gates at Bill Gates Catalyst 3 (bgc3) and at the Bill and Melinda Gates Foundation (BMGF). Dr. Nikolic received his MD from Zagreb Medical School and his clinical training from the University's Medical Center, University of Zagreb, Croatia. In 1994, Dr. Nikolic joined the Harvard Graduate Program in Immunology. Subsequently, Dr. Nikolic continued to serve in roles of increasing authority including postdoctoral fellowship, Instructor in Surgery and Medicine to Assistant Professor in Medicine at Harvard Medical School. Between 2002 and 2007, he led an advanced immunology laboratory for tolerance induction/stem cell transplantation in the Renal Unit, Massachusetts General Hospital/Harvard Medical School. In 2007, Dr. Nikolic BMGF and in 2010 he joined bgC3. Dr. Nikolic is the author of over 70 articles and patent applications and co-founder of three biotechnology companies.

• Lou Salkind – Board Member

  Lou Salkind is a managing director of D. E. Shaw & Co., L.P. and a member of the Executive Committee of D. E. Shaw & Co., L.P., a global investment firm whose activities center on various aspects of the intersection between technology and finance. Dr. Salkind received his A.B. from Princeton University in 1978, where he studied mathematics and physics, and his Ph.D. in 1990 from the Courant Institute of Mathematical Sciences at New York University, where he studied computer science and robotics. Dr. Salkind also serves on the board of the Union of Concerned Scientists, a non-profit organization that provides independent scientific analysis on a range of public policy issues.